In the past week, BCAB stock has gone down by -7.91%, with a monthly decline of -10.46% and a quarterly plunge of 0.00%. The volatility ratio for the week is 11.26%, and the volatility levels for the last 30 days are 12.79% for BioAtla Inc. The simple moving average for the past 20 days is 6.60% for BCAB’s stock, with a 26.14% simple moving average for the past 200 days.
Is It Worth Investing in BioAtla Inc (NASDAQ: BCAB) Right Now?
The 36-month beta value for BCAB is at 1.30. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for BCAB is 38.78M, and currently, shorts hold a 13.96% of that float. The average trading volume for BCAB on May 10, 2024 was 605.90K shares.
BCAB) stock’s latest price update
The stock price of BioAtla Inc (NASDAQ: BCAB) has dropped by -7.03 compared to previous close of 3.13. Despite this, the company has seen a fall of -7.91% in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-19 that SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, March 26, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2023 and provide business highlights.
Analysts’ Opinion of BCAB
Many brokerage firms have already submitted their reports for BCAB stocks, with JMP Securities repeating the rating for BCAB by listing it as a “Mkt Outperform.” The predicted price for BCAB in the upcoming period, according to JMP Securities is $17 based on the research report published on September 15, 2022 of the previous year 2022.
Credit Suisse, on the other hand, stated in their research note that they expect to see BCAB reach a price target of $5, previously predicting the price at $35. The rating they have provided for BCAB stocks is “Neutral” according to the report published on May 05th, 2022.
H.C. Wainwright gave a rating of “Buy” to BCAB, setting the target price at $25 in the report published on March 21st of the previous year.
BCAB Trading at 1.86% from the 50-Day Moving Average
After a stumble in the market that brought BCAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.47% of loss for the given period.
Volatility was left at 12.79%, however, over the last 30 days, the volatility rate increased by 11.26%, as shares sank -13.13% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.99% upper at present.
During the last 5 trading sessions, BCAB fell by -7.91%, which changed the moving average for the period of 200-days by +4.68% in comparison to the 20-day moving average, which settled at $2.71. In addition, BioAtla Inc saw 18.29% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCAB starting from MCBRINN SYLVIA, who purchase 4,000 shares at the price of $2.33 back on Dec 26 ’23. After this action, MCBRINN SYLVIA now owns 15,125 shares of BioAtla Inc, valued at $9,320 using the latest closing price.
SHORT JAY M PHD, the Chief Executive Officer of BioAtla Inc, purchase 50,000 shares at $2.14 during a trade that took place back on Dec 20 ’23, which means that SHORT JAY M PHD is holding 1,439,283 shares at $106,910 based on the most recent closing price.
Stock Fundamentals for BCAB
The total capital return value is set at -1.42. Equity return is now at value -98.37, with -71.49 for asset returns.
Based on BioAtla Inc (BCAB), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -42.28. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 88.22.
Currently, EBITDA for the company is -128.47 million with net debt to EBITDA at 0.85. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.11.
Conclusion
In conclusion, BioAtla Inc (BCAB) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
